Patents by Inventor Rohit Kshirsagar
Rohit Kshirsagar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11397630Abstract: A method, system and computer program product for improving the availability of API endpoints in container orchestration platforms. A service request handler module of a microservice application programming interface (API) fault manager (MAFM) invokes a microservice API fault management service in response to detecting an unresponsive microservice managed by a container orchestration platform. An API inspection module of the MAFM identifies an unresponsive API of the unresponsive microservice. A remedial action module of the MAFM determines a remedial action to correct an unresponsive state of the unresponsive API. A container platform interface module of the MAFM communicates the remedial action to the container orchestration platform.Type: GrantFiled: January 2, 2020Date of Patent: July 26, 2022Assignee: KYNDRYL, INC.Inventors: Shantanu Dutta, Bijo Sebastian Kappen, Sujith Rajeevakshan Pillai, Raj Kumar Teketi, Rohit Kshirsagar
-
Publication number: 20210208961Abstract: A method, system and computer program product for improving the availability of API endpoints in container orchestration platforms. A service request handler module of a microservice application programming interface (API) fault manager (MAFM) invokes a microservice API fault management service in response to detecting an unresponsive microservice managed by a container orchestration platform. An API inspection module of the MAFM identifies an unresponsive API of the unresponsive microservice. A remedial action module of the MAFM determines a remedial action to correct an unresponsive state of the unresponsive API. A container platform interface module of the MAFM communicates the remedial action to the container orchestration platform.Type: ApplicationFiled: January 2, 2020Publication date: July 8, 2021Applicant: International Business Machines CorporationInventors: Shantanu Dutta, Bijo Sebastian Kappen, Sujith Rajeevakshan Pillai, Raj Kumar Teketi, Rohit Kshirsagar
-
Patent number: 10717965Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.Type: GrantFiled: December 21, 2018Date of Patent: July 21, 2020Assignee: Gloriana Therapeutics, Inc.Inventors: Alan Gilbert, Kyle McElearney, Terrence Michael Dobrowsky, Rashmi Rohit Kshirsagar
-
Patent number: 10669523Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.Type: GrantFiled: December 21, 2018Date of Patent: June 2, 2020Assignee: Gloriana Therapeutics, Inc.Inventors: Alan Gilbert, Kyle McElearney, Terrence Michael Dobrowsky, Rashmi Rohit Kshirsagar
-
Patent number: 10590454Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.Type: GrantFiled: October 16, 2017Date of Patent: March 17, 2020Assignee: Biogen MA Inc.Inventors: Rashmi Rohit Kshirsagar, Alan Gilbert
-
Publication number: 20190194602Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.Type: ApplicationFiled: December 21, 2018Publication date: June 27, 2019Inventors: Alan Gilbert, Kyle McElearney, Terrence Michael Dobrowsky, Rashmi Rohit Kshirsagar
-
Patent number: 10308706Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.Type: GrantFiled: March 4, 2015Date of Patent: June 4, 2019Assignee: Biogen MA Inc.Inventors: David Evans, R. Blake Pepinsky, Dingyi Wen, Rashmi Rohit Kshirsagar, Karin Lucas
-
Publication number: 20180251805Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.Type: ApplicationFiled: October 16, 2017Publication date: September 6, 2018Applicant: Biogen MA Inc.Inventors: Rashmi Rohit Kshirsagar, Alan Gilbert
-
Patent number: 9790533Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.Type: GrantFiled: February 6, 2017Date of Patent: October 17, 2017Assignee: Biogen MA Inc.Inventors: Rashmi Rohit Kshirsagar, Alan Gilbert
-
Publication number: 20170247655Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.Type: ApplicationFiled: February 6, 2017Publication date: August 31, 2017Inventors: Rashmi Rohit KSHIRSAGAR, Alan Gilbert
-
Patent number: 9562252Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.Type: GrantFiled: May 11, 2012Date of Patent: February 7, 2017Assignee: Biogen MA Inc.Inventors: Rashmi Rohit Kshirsagar, Alan Gilbert
-
Publication number: 20170029859Abstract: The present invention pertains to a cell culture medium comprising dextran sulfate or a mixture of dextran sulfate and ferric citrate, and methods of using thereof. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with dextran sulfate or a mixture of dextran sulfate and ferric citrate.Type: ApplicationFiled: October 12, 2016Publication date: February 2, 2017Inventors: Alan Gilbert, Kyle McElearney, Terrence Michael Dobrowsky, Rashmi Rohit Kshirsagar
-
Publication number: 20150353883Abstract: The present invention pertains to a cell culture medium comprising dextran sulfate or a mixture of dextran sulfate and ferric citrate, and methods of using thereof. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with dextran sulfate or a mixture of dextran sulfate and ferric citrate.Type: ApplicationFiled: January 10, 2014Publication date: December 10, 2015Inventors: Alan GILBERT, Kyle MCELEARNEY, Terrence Michael DOBROWSKY, Rashmi Rohit KSHIRSAGAR
-
Publication number: 20150274808Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.Type: ApplicationFiled: March 4, 2015Publication date: October 1, 2015Inventors: David Evans, R. Blake Pepinsky, Dingyi Wen, Rashmi Rohit Kshirsagar, Karin Lucas
-
Patent number: 9005926Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.Type: GrantFiled: October 1, 2010Date of Patent: April 14, 2015Assignee: Biogen Idec Ma Inc.Inventors: David Evans, R. Blake Pepinsky, Dingyi Wen, Rashmi Rohit Kshirsagar, Karin Lucas
-
Publication number: 20120264916Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.Type: ApplicationFiled: October 1, 2010Publication date: October 18, 2012Applicant: Biogen Idec MA Inc.Inventors: David Evans, R. Blake Pepinsky, Dingyi Wen, Rashmi Rohit Kshirsagar, Karin Lucas